Overview of the Industry Sponsored Satellite Symposia.
THURSDAY, September 7, 2023 – Room B07-08
BREAKFAST SATELLITE SYMPOSIUM
Tarsier Pharma – 08:10 - 09:00 – ROOM: B07-08
Chairmen: Prof.Dr Marc de Smet, Prof.Dr Quan Dong Nguyen
Breaking the uveitic glaucoma vicious cycle
Announcing the TRS4Vision Phase III trial resultsChairmen: Prof.Dr Marc de Smet, Prof.Dr Quan Dong Nguyen
| 08:10 | Welcome |
| Prof.Dr. Marc de Smet & Prof.Dr. Quan Dong Nguyen | |
| 08:15 | Dazdotuftide - a novel first in class new anti-inflammatory drug |
| Dr.PhD Daphne Haim-Langford | |
| 08:20 | Challenges in managing uveitic glaucoma and the establishment of “vision protection score” |
| Prof.Dr. Marc de Smet | |
| 08:30 | TRS4Vision trial results |
| Dr.MD David Chu | |
| 08:50 | Panel-Discussion, further questions and final remarks |
| Prof.Dr. Marc de Smet & Prof.Dr. Quan Dong Nguyen | |
| 09:00 | END OF SYMPOSIUM |
LUNCH SATELLITE SYMPOSIUM
Roche Pharma AG – 12:55 - 13:45 – ROOM: B07-08
Ophthalmology Thinking Ahead -
Chairmen: Prof.Dr.med. Antonia Joussen, Berlin
Ophthalmology Thinking Ahead -
With an Eye on the Future
Chairmen: Prof.Dr.med. Antonia Joussen, Berlin| 12:55 | Welcome, scientific chair and moderation - Pathophysiology in DME and DR |
| Prof.Dr.med Antonia Joussen, Berlin | |
| 13:10 | An Actual Overview of Faricimab |
| Prof.Dr.med Oliver Zeitz, Berlin | |
| 13:25 | The Future of Roche in Ophthalmology |
| Dr. Stefan Scheidl, Roche Basel | |
| 13:40 | Panel-Discussion, further questions and final remarks |
| All, Chair Prof.Dr.med. Antonia Joussen, Berlin | |
| 13:45 | END OF SYMPOSIUM |
FRIDAY, September 8, 2023 – Room B07-08
BREAKFAST SATELLITE SYMPOSIUM
Carl Zeiss Limited – 08:10 - 09:00 – ROOM: B07-08
Uveitis Grand Rounds:
Faculty:
- Prof. Marion Munk,
- Prof. Francesco Pichi
In this session, our faculty will discuss various clinical cases of inflammatory disease. The cases will highlight how multimodal imaging can be used to differentiate and monitor inflammatory conditions. The cases discussions will be filled with images from wide-field fundus photography, fundus autofluorescence, OCT, and OCT angiography to enhance attendee understanding of how to integrate multimodal imaging into patient care.
Uveitis Grand Rounds:
Multimodal imaging guiding the way
Faculty:
- Prof. Marion Munk,
- Prof. Francesco Pichi
In this session, our faculty will discuss various clinical cases of inflammatory disease. The cases will highlight how multimodal imaging can be used to differentiate and monitor inflammatory conditions. The cases discussions will be filled with images from wide-field fundus photography, fundus autofluorescence, OCT, and OCT angiography to enhance attendee understanding of how to integrate multimodal imaging into patient care.
LUNCH SATELLITE SYMPOSIUM
Alimera Sciences / Horus Pharma – 12:55 - 13:45 – ROOM: B07-08
International Real-World Insights of Using a Long-term Intravitreal 0.2 µg/day Fluocinolone Acetonide Implant in NIU-PS
Chairmen: Professor Uwe Pleyer, Charité Universitätsmedizin Berlin, Germany and Professor Bahram Bodaghi, Sorbonne University, IHU FOReSIGHT, Pietié-Salpêtrière Hospital, France| 12:55 | Welcome and Introductions |
| Prof. Uwe PLEYER | |
| 12:57 | Treating Recurrent Non-Infectious Uveitis: An Overview of PSV-FAi-001 and PSV-FAi-005 |
| Prof. Quan NGUYEN | |
| 13:04 | Systemic Management of NIU-PS in Association with the 0.2 µg/day Fluocinolone Acetonide Intravitreal Implant |
| Dr. Sunil SRIVASTAVA | |
| 13:10 | Intraocular Inflammation Control and Changes in Choroidal Structure in NIU-PS |
| Prof. Carlos PAVESIO | |
| 13:16 | Intraocular Inflammation Control and Changes in Retinal Structure in NIU-PS |
| Prof. Uwe PLEYER | |
| 13:22 | What Clinical Presentations of NIU-PS Would You Use the 0.2 µg/day Fluocinolone Acetonide Intravitreal Implant? |
| Prof. Elisabetta MISEROCCHI | |
| 13:28 | Does Baseline Induced Quiescence Lead to Better Control of NIU-PS with the 0.2 µg/day Fluocinolone Acetonide Intravitreal Implant? |
| Prof. Bahram BODAGHI | |
| 13:34 | Conclusions |
| Prof. Bahram BODAGHI | |
| 13:40 | Q&A |
| 13:45 | End of Session |
SATURDAY, September 9, 2023 – Room B07-08
LUNCH SATELLITE SYMPOSIUM
Acelyrin – 12:55 - 13:45 – ROOM: B07-08
- Introduction: Unmet Needs in the Management of Non-infectious Uveitis Professor Quan Dong NGUYEN, MD, MSc, FARVO, FASRS (USA) - IL-17 in the Pathophysiology of Uveitis and the Potential Roles of IL-17 Inhibition Professor Jarmila HEISSIGEROVÁ, MUDr, PhD, MBA (Czech Republic) - Izokibep: A Novel Approach to IL-17 Inhibition – Advancements through Clinical Trials Dr. David R. P. ALMEIDA, MD, MBA, PhD (USA)/Professor Quan Dong NGUYEN, MD, MSc, FARVO, FASRS (USA) - Izokibep Study 21103 Dr. David D. HOELSCHER (USA) Panel Discussion with Audience Participation - Moderator: Professor Quan Dong NGUYEN, MD, MSc, FARVO, FASRS (USA) - Panelists: Dr. David R. P. ALMEIDA, MD, MBA, PhD (USA), Professor Bahram BODAGHI, MD, PhD (France), Professor Jarmila HEISSIGEROVÁ, MUDr, PhD, MBA (Czech Republic), Dr. David D. HOELSCHER (USA), Professor Uwe PLEYER, MD, PhD/I>
Drug Exposure May Be the Key
Chair: Quan Dong Nguyen, MD, MSc, FARVO, FASRS (USA)- Introduction: Unmet Needs in the Management of Non-infectious Uveitis Professor Quan Dong NGUYEN, MD, MSc, FARVO, FASRS (USA) - IL-17 in the Pathophysiology of Uveitis and the Potential Roles of IL-17 Inhibition Professor Jarmila HEISSIGEROVÁ, MUDr, PhD, MBA (Czech Republic) - Izokibep: A Novel Approach to IL-17 Inhibition – Advancements through Clinical Trials Dr. David R. P. ALMEIDA, MD, MBA, PhD (USA)/Professor Quan Dong NGUYEN, MD, MSc, FARVO, FASRS (USA) - Izokibep Study 21103 Dr. David D. HOELSCHER (USA) Panel Discussion with Audience Participation - Moderator: Professor Quan Dong NGUYEN, MD, MSc, FARVO, FASRS (USA) - Panelists: Dr. David R. P. ALMEIDA, MD, MBA, PhD (USA), Professor Bahram BODAGHI, MD, PhD (France), Professor Jarmila HEISSIGEROVÁ, MUDr, PhD, MBA (Czech Republic), Dr. David D. HOELSCHER (USA), Professor Uwe PLEYER, MD, PhD/I>